Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

Targeted Disease(s):
Pulmonary Fibrosis

Purpose of Study:

The purpose of this study is to compare the effectiveness and the safety of sarilumab in patients with glucocorticoid-dependent sarcoidosis. To demonstrate that sarilumab treatment will be effective for inducing and maintaining glucocorticoid-free remission in male or female patients with biopsy proven active, glucocorticoid-dependent sarcoidosis affecting the lungs, lymph nodes, liver, kidneys, spleen, bone, soft tissues, skin, and/or eyes.

Study Dates:
September 5, 2019 - July 2, 2025

Study Location:

Lead Institution:
Memorial Sloan Kettering, Fox Chase Cancer Center, Johns Hopkins Medical Center


Matthew Baker
[email protected]

Register for Trial
Freedom From Smoking Clinic
Detroit, MI | May 29, 2024
Asthma Basics Workshop - National
, | Jun 18, 2024